Pulmonary embolism
544 results
1 - 100
Pulmonary embolism - Thrombolytic therapy in pulmonary embolism
- Diagnosis of pulmonary embolism - Image
Imaging for the exclusion of pulmonary embolism in pregnancy- Thrombolytic therapy for pulmonary embolism
- Anticoagulant treatment for subsegmental pulmonary embolism
- D-dimer testing and pulmonary embolism
- Outpatient treatment for acute pulmonary embolism
- Vena caval filters for the prevention of pulmonary embolism
- Vena caval filters for the prevention of pulmonary embolism
Pulmonary embolism common in patients with first episode of syncope (PESIT)- D‐dimer test for excluding the diagnosis of pulmonary embolism
- Low prevalence of pulmonary embolism in patients who present to ED with syncope
- Pulmonary embolism rule-out criteria reduces the need for CT pulmonary angiography in low-risk patients (PERC)
- Pulmonary Embolism (PE) Severity Index predicts low risk PE patients.
- Outpatient versus inpatient treatment for acute pulmonary embolism
- Prophylaxis against deep vein thrombosis and pulmonary embolism in hip fracture surgery
- Safety of ruling out acute pulmonary embolism in outpatients by normal computed tomography pulmonary angiography
- Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
- Prevalence of pulmonary embolism is 5.9% in patients with COPD who are hospitalized with acute respiratory symptoms
- Extended anticoagulation for patients with low-risk pulmonary embolism and cancer has marginal benefit (ON COPE)
- Concurrent COVID-19 infection does not affect the sensitivity of D-dimer for pulmonary embolism diagnosis
- Risk of recurrent venous thromboembolism is 3% in patients with subsegmental pulmonary embolism who are not anticoagulated
- Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism
- Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures
- Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism